@phdthesis{oai:nagoya.repo.nii.ac.jp:00008921,
 author = {岩崎, 卓識 and Iwasaki, Takashi},
 month = {Sep},
 note = {P53 mutation has been reported in various solid tumors, acute leukemia and myelodysplastic syndrome (MDS). However, the diagnostic significance of p53 in MDS remains to be determined. We examined p53 mutation and immunostaining of the same patients, since there have been few reports of simultaneous analysis of these markers. Seven p53 mutations were observed among 37 MDS and 11 cases of overt leukemia transformed from MDS (MDS-OL). Mutated p53 mainly observed in high-risk MDS showed more intense p53 staining than those of MDS cases with wild-type p53 overexpression. Aplastic anemia (AA) showed no p53 staining. The percentage of p53 staining of MDS (71%) was higher than that of mutated p53 cases (11%) but did not reach 100% of MDS cases studied. Therefore, we tried to differentiate MDS, especially RA and AA using a combination of p53 immunostaining, HbF immunostaining and chromosome abnormality, because Hemoglobin F (HbF) of erythroblasts was reportedly observed in MDS refractory anemia (RA) but not in AA. Most MDS/MDS-OL (47/48) showed at least one positive marker, whereas 11 AA cases proved totally negative except for two positive HbF cases. Our results suggest that the combination of these three markers is useful to discriminate MDS from AA., 名古屋大学博士学位論文 学位の種類:博士(医療技術学) (課程) 学位授与年月日:平成20年9月30日},
 school = {名古屋大学, NAGOYA University},
 title = {The combination of karyotype analysis, HbF and p53 immunostaining is useful for the differential diagnosis between refractory anemia and aplastic anemia.},
 year = {2008}
}